PF-08634404 + Sigvotatug Vedotin + Combination Agent 1
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced/Metastatic Non-Small Cell Lung Cancer
Conditions
Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Trial Timeline
Jan 30, 2026 → Aug 23, 2033
NCT ID
NCT07227298About PF-08634404 + Sigvotatug Vedotin + Combination Agent 1
PF-08634404 + Sigvotatug Vedotin + Combination Agent 1 is a phase 1/2 stage product being developed by Pfizer for Advanced/Metastatic Non-Small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07227298. Target conditions include Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Advanced/Metastatic Non-Small Cell Lung Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
9
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07227298 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Advanced/Metastatic Non-Small Cell Lung Cancer